On the 7th of May 2019, the new evaluation for bone-anchored prosthesis has been commenced in a framework of New Method, which provides a way for a managed introduction of innovations into Norwegian health care system. The proposal for the assessment was submitted by Oslo University Hospital in order to receive an opportunity to offer this method to achieve overall money saving and medical benefits as nowadays, only conventional prostheses are offered, and patients are sent to Gothenburg to receive the treatment, that is financed by the Norwegian health service.

Disease management programs (DMPs) should be updated on a regular basis in order to adapt them to the current medical knowledge level. The Institute for Quality and Efficiency in Health Care (IQWiG) has thus researched current evidence-based guidelines on diabetes mellitus type 2, summarized their recommendations and checked the need for DMP update.

In May 2019, the Galician Agency for Health Technology Assessment, AVALIA-T, has released a report “Diagnostic and clinical utility of cerebral amyloid PET in mild cognitive impairment, Alzheimer's disease, and other dementias.”

In May 2019, the National Institute for Health and Care Excellence published two new medical technology guidance for negative pressure wound dressings and preventing infections when using needleless connectors, and three new MedTech innovation briefings for pressure ulcer prevention, midstream urine collection and preserving vascular grafts.

On April 18, 2019, the Nomenclature was updated. The update brought changes in chapter V of Nomenclature, regarding the creation of new codes for ultrasound examination during pregnancy.

In early May 2019, the Austrian HTA body, the Ludwig-Boltzmann Institute (LBI), has published a health technology assessment on robot-assisted surgery in thoracic and visceral indications as part of the EUnetHTA work.

A syndicated report (>80 pages) includes the overview and statistics of 16 key innovation funding and coverage with evidence development schemes in seven European countries: Austria, Belgium, England, France, Germany, the Netherlands and Switzerland. The price of the report is €1600.

The report presents a summary of reimbursement situation for total and partial hip replacement in Europe. The following indications will be considered: coxarthrosis, osteonecrosis. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.

In March 2019, NICE published an updated version of its evidence standards framework for digital health technologies (DHTs) that sets out the evidence requirements for different types of DHTs.

The report presents a summary of reimbursement situation for mammography in ambulatory settings. All procedure codes for different types of mammography will be provided in the analysis. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.

On the 24th of April 2019, the French Technical Agency for Hospital Information (ATIH) has released a technical note in connection with the 2019 DRG changes. Several key updates in relation to the financing of hospitalization benefits as a change of DRGs for fractional flow reserve, package to finance the rehabilitation and infusion costs of the pulmonary system and implementation of two innovative packages for PULSANTE and WISE CRT devices were outlined.

The Clinical Coding and Schedule Development (CCSD) group develop and maintains procedural and diagnostics nomenclature for private payers in England. New procedure codes concern cytoreductive surgery for colorectal peritoneal carcinomatosis, cytoreductive surgery for ovarian malignancies, therapeutic sialendoscopy, intra corporeal salivary gland lithotripsy, and others and diagnostic codes for tests for common and rare mutations.